Study Questions Effectiveness of Budesonide for Preterm Infants with BPD
A recent study from the Royal Women’s Hospital reveals that combining budesonide with surfactant may not significantly improve survival rates free from bronchopulmonary dysplasia (BPD) in extremely preterm infants. Published in JAMA, the PLUSS trial involved over 1,000 infants and highlights the complexities of treating BPD, a common respiratory condition in preterm babies. Further research is essential to refine treatment protocols and enhance neonatal care.
Triple Inhaled Therapy Reduces Cardiopulmonary Risk in COPD Patients
Learn about the promising results of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate in reducing the risk of cardiopulmonary events in individuals with COPD. The post-hoc analysis based on the ETHOS phase 3 clinical trial showed a 20% reduction in risk compared to dual therapy, offering hope for improved outcomes and enhanced quality of life for COPD patients.